Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat.

Giuliano F, Clément P, Droupy S, Alexandre L, Bernabé J

Neuroscience19 Dec 2005Cited by 14 (Europe PMC)

PMID16360286DOI10.1016/j.neuroscience.2005.11.008PepBankPUB-16360286

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In anaesthetized rats, MTII given intravenously or into the paraventricular nucleus dose-dependently elicited erectile events.
In plain wordsIn anaesthetized rats, MTII given into a vein or a brain area caused erections in a dose-dependent way.
Peptide
Melanotan II
Outcome
IncreaseErectile events (inducer activity)
Study
ratn: not reported in source
anaesthetized rats
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
0.1, 0.3 and 1 mg/kg i.v.; 0.1 and 1 microg in paraventricular nucleus · intravenous or paraventricular nucleus of the hypothalamusAs given in this study (rat).
Source sentences
Summary
Delivered i.v. (0.1, 0.3 and 1 mg/kg) or within the paraventricular nucleus of the hypothalamus (0.1 and 1 microg), melanotan-II exerted a dose-dependent inducer activity on erection by eliciting erectile events and shortening latency of the first erectile event to occur.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats.
Report a problemFND-1636028601
02AnimalAnimal study (in vivo)Efficacy outcome
In anaesthetized rats, MTII given intravenously or into the paraventricular nucleus dose-dependently shortened the latency to the first erectile event.
In plain wordsIn anaesthetized rats, MTII given into a vein or a brain area shortened the time to the first erection.
Peptide
Melanotan II
Outcome
DecreaseLatency of the first erectile event
Study
ratn: not reported in source
anaesthetized rats
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
0.1, 0.3 and 1 mg/kg i.v.; 0.1 and 1 microg in paraventricular nucleus · intravenous or paraventricular nucleus of the hypothalamusAs given in this study (rat).
Source sentences
Summary
Delivered i.v. (0.1, 0.3 and 1 mg/kg) or within the paraventricular nucleus of the hypothalamus (0.1 and 1 microg), melanotan-II exerted a dose-dependent inducer activity on erection by eliciting erectile events and shortening latency of the first erectile event to occur.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats.
Report a problemFND-1636028602
03AnimalAnimal study (in vivo)Efficacy outcome
In anaesthetized rats, intrathecal MTII at the L6-S1 level produced erectile events of higher amplitude than intrathecal vehicle.
In plain wordsIn anaesthetized rats, MTII given into the spinal canal caused stronger erections than vehicle.
Peptide
Melanotan II
Outcome
IncreaseAmplitude of erectile events with intrathecal MTII
Study
ratn: not reported in source
anaesthetized rats
Comparator
Vehicle intrathecal
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
0.2 microg · intrathecal (L6-S1 level)As given in this study (rat).
Source sentences
Summary
Erectile events were of higher amplitude in rats treated with melanotan-II i.t. (0.2 microg) delivered at the L6-S1 level than in animals treated with the vehicle i.t. delivered.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats.
Report a problemFND-1636028603
04AnimalAnimal study (in vivo)Efficacy outcome
In anaesthetized rats, intravenous MTII increased erectile responses elicited by cavernous nerve stimulation.
In plain wordsIn anaesthetized rats, MTII given into a vein increased erections triggered by nerve stimulation.
Peptide
Melanotan II
Outcome
IncreaseErectile response to cavernous nerve stimulation (facilitator effect)
Study
ratn: not reported in source
anaesthetized rats
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
1 mg/kg · intravenousAs given in this study (rat).
Source sentences
Summary
Erectile responses elicited by cavernous nerve stimulation were increased after i.v. melanotan-II (1 mg/kg), thereby exerting facilitator effect on erection.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats.
Report a problemFND-1636028604
05AnimalAnimal study (in vivo)Efficacy outcome
In anaesthetized rats, MTII injected into the corpus cavernosum did not show a facilitator effect on erection.
In plain wordsIn anaesthetized rats, MTII injected into the penile erectile tissue did not boost nerve-triggered erections.
Peptide
Melanotan II
Outcome
No significant changeFacilitator effect with intracavernosal MTII
Study
ratn: not reported in source
anaesthetized rats
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
1 microg · intracavernosalAs given in this study (rat).
Source sentences
Summary
In contrast, melanotan-II injected within the corpus cavernosum (1 microg) did not display any facilitator activity.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats.
Report a problemFND-1636028605
06AnimalAnimal study (in vivo)Mechanism
In anaesthetized rats, spinalization and transection of pelvic or dorsal penile nerves did not impair the facilitator effect of intravenous MTII.
In plain wordsIn anaesthetized rats, cutting the spinal cord or pelvic and penile nerves did not stop MTII from boosting erections.
Peptide
Melanotan II
Outcome
No significant changeFacilitator effect after spinalization or pelvic or dorsal penile nerve transection
Study
ratn: not reported in source
anaesthetized rats
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
1 mg/kg · intravenousAs given in this study (rat).
Source sentences
Summary
Neither spinalization nor bilateral transection of pelvic nerves or dorsal penile nerves impaired facilitator activity of i.v. melanotan-II (1 mg/kg).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats.
Report a problemFND-1636028606
07AnimalAnimal study (in vivo)Mechanism
In anaesthetized rats, removal of the lumbar paravertebral sympathetic chain abolished the facilitator effect of intravenous MTII.
In plain wordsIn anaesthetized rats, removing the lumbar sympathetic nerve chain stopped MTII from boosting erections.
Peptide
Melanotan II
Outcome
DecreaseFacilitator effect after lumbar sympathetic chain removal
Study
ratn: not reported in source
anaesthetized rats
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
1 mg/kg · intravenousAs given in this study (rat).
Source sentences
Summary
Conversely, the facilitator effect of melanotan-II was abolished after acute removal of the lumbar paravertebral sympathetic chain.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats.
Report a problemFND-1636028607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.